Practical Approaches to Care in Emergency Syncope
PACES
3 other identifiers
observational
1,297
1 country
5
Brief Summary
Syncope, or transient loss of consciousness, is a common reason for visit to the Emergency Department and often leads to extensive testing and hospitalization. Using objective risk scores to determine which patients with syncope will actually benefit from these interventions, and which can be safely discharged home with minimal testing, is critical to providing sensible medical care. This study will evaluate the validity of two syncope risk-stratification tools and investigate their impact on healthcare utilization and patient safety, thus improving the quality of care for the 1-2 million patients who experience syncope every year in the United States
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2020
CompletedFirst Posted
Study publicly available on registry
August 31, 2020
CompletedStudy Start
First participant enrolled
September 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2024
CompletedApril 3, 2025
April 1, 2025
4 years
August 27, 2020
April 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
US Syncope Risk Score (The FAINT Score)
A combination of clinical, electrocardiographic, and laboratory variables to predict the risk of serious clinical outcomes at 30 days. Full scale range from 0-6, higher score indicates higher risk of a serious cardiac event or death.
30 days
Canadian Syncope Risk Score
A combination of clinical, electrocardiographic, and laboratory variables to predict the risk of serious clinical outcomes at 30 days. Full scale range from -3 to 11, higher score indicates higher risk of a serious clinical event or death.
30 days
Study Arms (1)
Patients with syncope
Patients who present to the ED with syncope
Eligibility Criteria
Adult patients who presents to the Emergency Department (ED) after an episode of syncope or pre-syncope and who do not have a new serious diagnosis found during the index ED evaluation. There are no exclusions based on sex/gender, race, or ethnicity.
You may qualify if:
- Adult patients 40 years of age or older who present to the Emergency Department with syncope or presyncope.
- Subjects must read and speak English or Spanish.
- Subjects must have a working phone number and fixed address.
You may not qualify if:
- Patient who have a syncope mimic such as seizure, stroke, head trauma with loss of consciousness, altered mental status, hypoglycemia, intoxication, or require an intervention to restore consciousness.
- Patients who have a new serious diagnosis found in the Emergency Department, such as death, significant cardiac arrhythmia (see below), myocardial infarction, significant structural heart disease, stroke (both ischemic and hemorrhagic), pulmonary embolism, aortic dissection, hemorrhage or anemia requiring blood transfusion, subarachnoid hemorrhage, cardiopulmonary resuscitation, acute surgical illness, pregnancy, or major traumatic injury.
- Significant cardiac arrhythmia includes Ventricular Fibrillation, Ventricular tachycardia (\>30 secs), Symptomatic ventricular tachycardia, (\<30 secs), Sick sinus disease with alternating sinus bradycardia and tachycardia, Sinus pause \> 3 seconds, Mobitz type II atrioventricular heart block, Complete heart block, Symptomatic supraventricular tachycardia (including Paroxysmal Supraventricular Tachycardia (PSVT), rapid atrial fibrillation/ flutter), Symptomatic bradycardia (pulse\<40), Pacemaker or implantable cardioverter-defibrillator malfunction with cardiac pauses.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
UC Davis
Sacramento, California, 95817, United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029-6574, United States
Columbia University Irving Medical Center
New York, New York, 10032, United States
University of Rochester
Rochester, New York, 14642, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Related Publications (4)
Probst MA, Kanzaria HK, Gbedemah M, Richardson LD, Sun BC. National trends in resource utilization associated with ED visits for syncope. Am J Emerg Med. 2015 Aug;33(8):998-1001. doi: 10.1016/j.ajem.2015.04.030. Epub 2015 Apr 24.
PMID: 25943042BACKGROUNDProbst MA, Gibson T, Weiss RE, Yagapen AN, Malveau SE, Adler DH, Bastani A, Baugh CW, Caterino JM, Clark CL, Diercks DB, Hollander JE, Nicks BA, Nishijima DK, Shah MN, Stiffler KA, Storrow AB, Wilber ST, Sun BC. Risk Stratification of Older Adults Who Present to the Emergency Department With Syncope: The FAINT Score. Ann Emerg Med. 2020 Feb;75(2):147-158. doi: 10.1016/j.annemergmed.2019.08.429. Epub 2019 Oct 23.
PMID: 31668571BACKGROUNDThiruganasambandamoorthy V, Kwong K, Wells GA, Sivilotti MLA, Mukarram M, Rowe BH, Lang E, Perry JJ, Sheldon R, Stiell IG, Taljaard M. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. CMAJ. 2016 Sep 6;188(12):E289-E298. doi: 10.1503/cmaj.151469. Epub 2016 Jul 4.
PMID: 27378464BACKGROUNDWongtanasarasin W, Nishijima DK, Wood N, DeAngelis J, Storrow A, Schimmel J, Beltre N, Sacco D, Probst MA. Factors associated with incentive redemption among participants in a multicenter prospective syncope clinical study. Acad Emerg Med. 2024 Dec;31(12):1276-1279. doi: 10.1111/acem.14979. Epub 2024 Jun 28. No abstract available.
PMID: 38940329BACKGROUND
Related Links
Biospecimen
Blood for cardiac biomarker testing.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marc A Probst, MD, MS
Columbia University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 27, 2020
First Posted
August 31, 2020
Study Start
September 14, 2020
Primary Completion
September 30, 2024
Study Completion
September 30, 2024
Last Updated
April 3, 2025
Record last verified: 2025-04